Gokmen Umut Erdem1, Mutlu Dogan2, Aydin Aytekin3, Suleyman Sahin4, Havva Yeşil Cinkir5, Abdullah Sakin6, Melike Ozcelik7, Oktay Bozkurt8, Emel Sezer9, Nebi Serkan Demirci10, Yakup Bozkaya11, Nurullah Zengin2. 1. Department of Medical Oncology, Kocaeli Derince Training and Research Hospital, 41310, Kocaeli, Turkey. gokmenumut@hotmail.com. 2. Department of Medical Oncology, Ankara Numune Training and Research Hospital, Ankara, Turkey. 3. Department of Medical Oncology, Medical Faculty of Gazi University, Ankara, Turkey. 4. Department of Medical Oncology, Van Training and Research Hospital, Van, Turkey. 5. Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey. 6. Department of Medical Oncology, Okmeydani Training and Research Hospital, İstanbul, Turkey. 7. Department of Medical Oncology, Kartal Training and Research Hospital, İstanbul, Turkey. 8. Department of Medical Oncology, Medical Faculty of Erciyes University, Kayseri, Turkey. 9. Department of Medical Oncology, Medical Faculty of Mersin University, Mersin, Turkey. 10. Department of Medical Oncology, Tekirdag State Hospital, Tekirdag, Turkey. 11. Department of Medical Oncology, Edirne State Hospital, Edirne, Turkey.
Abstract
OBJECTIVES: There is not yet a standardized approach to treat patients with small cell carcinoma of the bladder (SmCCB). This study aims to investigate the clinical features, treatment, and survival outcomes of patients with pure SmCCB. MATERIALS AND METHODS: Patients diagnosed with SmCCB between January 2006 and September 2015 were retrospectively evaluated. RESULTS: A total of 34 patients with a median age of 63.0 years were included in the study, with a male to female ratio of 4.6:1.0. At the time of diagnosis, 22 patients (64.7%) had stage IV disease. At a median follow-up time of 12.7 months, 67.6% of patients died of bladder carcinoma, with an overall survival (OS) of 15.7 months for all patients. In the patients with stages I-III, nodal involvement, and distant metastases, the median OS was 31.8, 15.7, and 8.4 months, respectively (P = 0.005). Considering the survival rates of the patients (stages I-III) treated with surgery vs. local therapy, there was not a statistically significant difference (26.6 months and 31.8 months, P = 0.97, respectively). A multivariate analysis revealed that stage IV disease and poor ECOG performance status were associated with OS. CONCLUSION: The optimal treatment of SmCCB has been under debate. For the patients with advanced stage of disease (T4b, N+, M+), platinum containing chemotherapeutic agents should be preferred. Stage IV disease and poor ECOG performance status were associated with shorter OS.
OBJECTIVES: There is not yet a standardized approach to treat patients with small cell carcinoma of the bladder (SmCCB). This study aims to investigate the clinical features, treatment, and survival outcomes of patients with pure SmCCB. MATERIALS AND METHODS:Patients diagnosed with SmCCB between January 2006 and September 2015 were retrospectively evaluated. RESULTS: A total of 34 patients with a median age of 63.0 years were included in the study, with a male to female ratio of 4.6:1.0. At the time of diagnosis, 22 patients (64.7%) had stage IV disease. At a median follow-up time of 12.7 months, 67.6% of patients died of bladder carcinoma, with an overall survival (OS) of 15.7 months for all patients. In the patients with stages I-III, nodal involvement, and distant metastases, the median OS was 31.8, 15.7, and 8.4 months, respectively (P = 0.005). Considering the survival rates of the patients (stages I-III) treated with surgery vs. local therapy, there was not a statistically significant difference (26.6 months and 31.8 months, P = 0.97, respectively). A multivariate analysis revealed that stage IV disease and poor ECOG performance status were associated with OS. CONCLUSION: The optimal treatment of SmCCB has been under debate. For the patients with advanced stage of disease (T4b, N+, M+), platinum containing chemotherapeutic agents should be preferred. Stage IV disease and poor ECOG performance status were associated with shorter OS.
Entities:
Keywords:
Bladder; Chemotherapy; Neuroendocrine carcinoma; Small cell carcinoma; Surgery
Authors: Dharam Kaushik; Igor Frank; Stephen A Boorjian; John C Cheville; Manuel S Eisenberg; Prabin Thapa; Robert F Tarrell; R Houston Thompson Journal: Int J Urol Date: 2015-03-11 Impact factor: 3.369
Authors: Arlene O Siefker-Radtke; Colin P Dinney; Neil A Abrahams; Cesar Moran; Yu Shen; Louis L Pisters; H Barton Grossman; David A Swanson; Randall E Millikan Journal: J Urol Date: 2004-08 Impact factor: 7.450
Authors: Sanjay G Patel; C J Stimson; Harras B Zaid; Matthew J Resnick; Michael S Cookson; Daniel A Barocas; Sam S Chang Journal: J Urol Date: 2013-09-12 Impact factor: 7.450